NASDAQ$TXG
10X Genomics Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported a revenue increase of 34% year-over-year, driven by strong customer demand and product innovation.
10x Genomics reported a strong first quarter with revenue of $71.9 million, a 34% increase compared to the same period in 2019. The company highlighted its commitment to supporting customers in combating the COVID-19 pandemic and expressed confidence in future opportunities despite macro uncertainties. However, they withdrew their annual revenue guidance for 2020 due to the evolving environment and continued uncertainties from the impact of COVID-19.
- Revenue reached $71.9 million, a 34% increase year-over-year.
- Gross margin was 79%, up from 74% in the prior year period, driven by lower accrued royalties related to ongoing litigation.
- Operating loss was $19.9 million, compared to $3.0 million in the prior year period, impacted by increased operating expenses.
- Cash and cash equivalents were $372.4 million as of March 31, 2020, including the impact of repaying term loan borrowings.
Headline financials
Revenue & EPS history
10X Genomics · Revenue · Quarterly
$71.9M
Revenue by segment
10X Genomics · $149M total across 4 segments · Q3 2023
- Single Cell Consumables$100M—67.2%
- Spatial Instruments$22.7M—15.2%
- Spatial Consumables$14.1M—9.4%
- Single Cell Instruments$12.2M—8.2%
Forward guidance
10x Genomics withdrew its annual revenue guidance for 2020 due to the evolving environment and continued uncertainties from the impact of COVID-19. The COVID-19 pandemic is a highly fluid situation and it is not currently possible for the Company to reasonably estimate the impact it may have on financial and operating results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+2.1%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+2.0%
Avg return
30 days after
58%
15 / 26 earnings
Positive
+17.3%
Q3 2025
Best reaction
-21.9%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.6% | -5.9% | +38.4% | |
| Q4 2025 | +3.5% | +11.8% | +7.3% | |
| Q3 2025 | +17.3% | +28.4% | +36.7% | |
| Q1 2025 | +1.3% | +5.7% | +9.2% | |
| Q4 2024 | -0.5% | +0.6% | -13.8% | |
| Q3 2024 | +4.0% | +3.0% | -2.4% | |
| Q2 2024 | +12.7% | +18.8% | +18.8% | |
| Q1 2024 | -5.2% | -3.2% | -21.1% | |
| Q4 2023 | +0.8% | -1.3% | -24.4% | |
| Q3 2023 | +15.7% | +13.7% | +33.3% | |
| Q2 2023 | -4.5% | -7.7% | -7.9% | |
| Q1 2023 | +5.9% | +5.5% | +5.7% | |
| Q4 2022 | +14.8% | +15.2% | +7.5% | |
| Q3 2022 | +13.0% | +9.5% | +38.1% | |
| Q2 2022 | +5.4% | +13.2% | -24.0% | |
| Q1 2022 | -0.5% | -6.4% | -10.6% | |
| Q4 2021 | -15.0% | -14.4% | -26.7% | |
| Q3 2021 | +12.7% | +7.7% | -14.9% | |
| Q2 2021 | -1.8% | -3.3% | +3.7% | |
| Q1 2021 | -21.9% | -27.1% | -2.6% | |
| Q4 2020 | -3.1% | -7.1% | -7.6% | |
| Q3 2020 | +1.8% | +3.3% | +11.4% | |
| Q2 2020 | +0.6% | +6.0% | +17.1% | |
| Q1 2020 | -0.4% | -6.0% | +3.1% | |
| Q4 2019 | -2.1% | -11.4% | -40.6% | |
| Q3 2019 | +3.1% | +10.3% | +17.3% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro